Intellikine Launches INK1117 Phase I Study

The Phase I study is to evaluate the safety, tolerability and pharmacokinetic profile of INK1117 in patients with advanced solid malignancies.

Biotherapeutics company Intellikine has initiated a multicentre Phase I dose escalation study of INK1117, a selective, orally available, small molecule inhibitor of the PI3Kalpha isoform, in patients with advanced solid malignancies.

The Phase I study is to evaluate the safety, tolerability and pharmacokinetic profile of the PI3Kalpha selective inhibitor.

In PI3Kalpha mutant-specific preclinical tumour models, INK1117 has demonstrated good efficacy results.

INK1117 will be explored in cancer patients, particularly those whose tumours have a mutation of the PIK3CA gene.